Key Highlights

  • bioAffinity Technologies (NASDAQ:BIAF) fell 3.17% pre-market to a listed USD 3.63 on 323 shares, with a market capitalization of USD 5 million and an RSI of 33.9 labeled Down.
  • bioAffinity Technologies, a diagnostics company focused on early lung cancer detection, fell 3.17% to USD 3.63 pre-market on only 323 shares.
  • The market value is USD 5 million and the RSI of 33.9 is weak.
  • No company release dated October 14 was found, and the stock gained 2.98% from the open after a 9.74% gap lower.

The Latest Verified Updates

No company release dated October 14 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. bioAffinity Technologies is a diagnostics company focused on early lung cancer detection, and it fell 3.17% pre-market to USD 3.63 on only 323 shares. A search of company filings and wire releases found no announcement dated October 14, and the screener lists no catalyst. The stock gapped 9.74% lower and recovered 2.98% from the pre-market open, so the day began with a sharp drop.

The Data Behind the Move

A 323-share print equals roughly USD 1,200 of traded value, simple arithmetic, against a USD 5 million market value. The RSI of 33.9 labeled Down shows weak momentum. Frequent financing needs make dilution the main risk for micro-cap diagnostics companies. If the listed price is the pre-market quote, simple arithmetic puts the prior close near USD 3.75; if it is the last close, the implied pre-market price is near USD 3.51, so check a live quote. Pre-market traded value is only about USD 0.00 million, a tiny slice of the company's size, so few dollars set the price. Volume of 323 shares is very thin, under 1,000 shares, and the screener tag reads No catalyst found, which classifies the catalyst and does not set direction.

Risks and What to Watch

A USD 5 million market value, thin trading and financing needs make the stock volatile. What to watch next: financing and company filings. This is information only and not investment advice. On Wednesday morning the SPY ETF was up about 0.2% and the QQQ ETF was roughly flat, with Bank of America and Morgan Stanley reporting earnings and September CPI data due. Tech stocks fell on October 8 on worries about OpenAI's revenue, with the Nasdaq 100 down 1.4% and the Philadelphia Semiconductor Index down 3.4%, and AI hardware names remain sensitive to that theme. The Fed raised rates in September and meets again on October 27 and 28, and the 10-year Treasury yield touched about 5.35% on October 7, the highest since 2002. Oil traded above USD 100 a barrel on Iran and Strait of Hormuz supply risks, which keeps inflation and rate worries in focus.

Where Things Stand

Market conditions frame the day: S&P 500 futures were slightly higher, big banks report and CPI is due, while AI hardware stocks stay sensitive to OpenAI revenue worries. bioAffinity Technologies (NASDAQ:BIAF) is moving with thin pre-market trading with no company release. A pre-market drop on this volume can reverse once regular trading opens, so the balance of evidence favors waiting for confirmation from filings and the open. Direction remains unknown, and the next catalyst is financing and company filings. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.